Chuck Royce's CPRX Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 2.03 M shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $40.09 M, representing 0.40% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in CPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 844,521 shares. Largest reduction occurred in Q3 2022, reducing 1.44 M shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Chuck Royce
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2019 | +780,782 | New Buy | 780,782 | $3.75 |
| Q1 2020 | -136,791 | Reduce 17.52% | 643,991 | $3.85 |
| Q2 2020 | +665,915 | Add 103.40% | 1.31 M | $4.62 |
| Q3 2020 | +474,984 | Add 36.26% | 1.78 M | $2.97 |
| Q4 2020 | +620,239 | Add 34.75% | 2.41 M | $3.34 |
| Q1 2021 | +844,521 | Add 35.11% | 3.25 M | $4.61 |
| Q2 2021 | -175,804 | Reduce 5.41% | 3.07 M | $5.75 |
| Q3 2021 | -66,852 | Reduce 2.17% | 3.01 M | $5.30 |
| Q4 2021 | -423,126 | Reduce 14.07% | 2.58 M | $6.77 |
| Q1 2022 | -321,961 | Reduce 12.46% | 2.26 M | $8.29 |
| Q2 2022 | -161,682 | Reduce 7.15% | 2.1 M | $7.01 |
| Q3 2022 | -1.44 M | Reduce 68.64% | 658,547 | $12.83 |
| Q4 2022 | -126,658 | Reduce 19.23% | 531,889 | $18.60 |
| Q1 2023 | +84,079 | Add 15.81% | 615,968 | $16.58 |
| Q2 2023 | +424,020 | Add 68.84% | 1.04 M | $13.44 |
| Q3 2023 | +571,714 | Add 54.97% | 1.61 M | $11.69 |
| Q4 2023 | +131,372 | Add 8.15% | 1.74 M | $16.81 |
| Q1 2024 | +340,939 | Add 19.56% | 2.08 M | $15.94 |
| Q2 2024 | +78,009 | Add 3.74% | 2.16 M | $15.49 |
| Q3 2024 | -140,917 | Reduce 6.52% | 2.02 M | $19.88 |
| Q4 2024 | -156,754 | Reduce 7.76% | 1.86 M | $20.87 |
| Q1 2025 | -265,991 | Reduce 14.27% | 1.6 M | $24.25 |
| Q2 2025 | -15,498 | Reduce 0.97% | 1.58 M | $21.70 |
| Q3 2025 | +452,103 | Add 28.56% | 2.03 M | $19.70 |
Chuck Royce's Catalyst Pharmaceuticals Investment FAQs
Chuck Royce first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q4 2019, acquiring 780,782 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Catalyst Pharmaceuticals, Inc. (CPRX) for 24 quarters since Q4 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q1 2021, adding 3,249,650 shares worth $14.98 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Chuck Royce's firm, Royce & Associates Lp, owns 2,034,965 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $40.09 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.40% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 3,249,650 shares, as reported at the end of Q1 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.